Abstracts tagged "Rheumatoid arthritis (RA)"

Abstract Number: 2379 • 2019 ACR/ARP Annual Meeting
High Initial Methotrexate Dose Is Not Associated with an Increased Risk of Liver Toxicity in Korean Patients with Rheumatoid Arthritis
Se Rim Choi¹, Yeong-Wook Song ², Eun Bong Lee ³ and Jin Kyun Park ¹, ¹Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, Seoul, Republic of Korea, ²Seoul National University Hospital, Seoul, Republic of Korea, ³Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, seoul
Background/Purpose: Methotrexate (MTX) is the most commonly prescribed disease modifying anti-rheumatic drugs (DMARDs) for the treatment of RA due to its high efficacy and favorable…
Abstract Number: 2460 • 2019 ACR/ARP Annual Meeting
Frailty in Ankylosing Spondylitis, Psoriatic Arthritis, and Rheumatoid Arthritis: Data from a National Claims Database
Sarah Lieber¹, Mangala Rajan ², Sebastian E. Sattui ¹, Geyanne Lui ³, Sergio Schwartzman ⁴, Lisa Mandl ⁴ and Iris Navarro-Millan ², ¹Hospital for Special Surgery, New York, ²Weill Cornell Medicine, New York, ³Weill-Cornell Medicine, New York, NY, ⁴Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, New York, NY
Background/Purpose: Frailty, a state of decreased homeostatic reserve, is associated with increased disability and mortality, independent of age. Frailty has been evaluated in large datasets…
Abstract Number: 2850 • 2019 ACR/ARP Annual Meeting
Exploring Heterogeneity in Rheumatoid Arthritis: Outcomes up to 4 Years of Follow-Up in Patient Clusters Identified by Data-driven Analysis of the BRASS Registry
Jeffrey Curtis¹, Michael Weinblatt ², Kenneth Saag ¹, Vivian Bykerk ³, Christina Charles-Schoeman ⁴, Stefano Fiore ⁵, Gregory St John ⁶, Toshio Kimura ⁷, Shen Zheng ⁵, Clifton Bingham ⁸, Grace Wright ⁹, Martin Bergman ¹⁰, Kamala Nola ¹¹, Daniel Furst ⁴ and Nancy Shadick ², ¹University of Alabama at Birmingham, Birmingham, AL, ²Brigham and Women's Hospital, Boston, MA, ³Hospital for Special Surgery, New York City, NY, ⁴University of California, Los Angeles, CA, ⁵Sanofi Genzyme, Bridgewater, NJ, ⁶Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁷Regeneron Pharmaceuticals, Inc, Tarrytown, NY, ⁸Johns Hopkins University, Baltimore, MD, ⁹Private Practice, New York City, NY, ¹⁰Drexel University College of Medicine, Stockholm, Sweden, ¹¹Lipscomb University College of Pharmacy & Health Sciences, Nashville, TN
Background/Purpose: Patients with rheumatoid arthritis (RA) may share characteristics that relate to their future outcomes. We investigated clinical outcomes over a 4-year follow-up period in…
Abstract Number: 7 • 2019 ACR/ARP Annual Meeting
Citrullination of Interleukin 6 Augments Its Pro-inflammatory Capacity and Signaling Potency Through Interleukin-6 Receptor in Rheumatoid Arthritis
Chenyang Lu ¹, Ray Ohara ², Phillip Campbell ¹, Yuxuan Du ³, Alexander Stinson ², Jonatan Hervoso ³, Ellen Cealey ³, David Fox ⁴ and M Amin⁵, ¹the University of Michigan, Ann Arbor, MI, ²Washington University, St. Louis, MO, ³the University of Michigan, Ann Arbor, ⁴University of Michigan, Ann Arbor, ⁵University of Michigan, Ann Arbor, MI
Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory disorder featured by synovial hyperplasia, inflammatory cell infiltration and presence of anti-citrullinated peptide antibodies (ACPAs) in sera.…
Abstract Number: 58 • 2019 ACR/ARP Annual Meeting
In Rheumatoid Arthritis (RA) Decreases in Conventional Dendritic Cell Lineages Are Associated with Adverse Measures of Myocardial Function and Expansions of Anomalous HLA-DR+ Myeloid Subsets
Christian Geier¹, Jon Giles ², Gilad Gibor ³, Joan Bathon ² and Robert Winchester ³, ¹Columbia University, New York, NY, ²Division of Rheumatology, Columbia University, New York, NY, ³Columbia University, New York
Background/Purpose: Dendritic cells (DC) are specialized antigen-presenting cells (APC) that have a central role in the initiation of immune responses. However, prior studies showed numeric decreases…
Abstract Number: 189 • 2019 ACR/ARP Annual Meeting
Validation of Claims-based Algorithms to Identify Interstitial Lung Disease in Patients with Rheumatoid Arthritis
Soo-Kyung Cho¹, Tracy J. Doyle ², Hemin Lee ³, Yinzhu Jin ³, Angela Y. Tong ³, Adrian J. Santiago Ortiz ³, Jeffrey Sparks ⁴ and Seoyoung C. Kim ³, ¹Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ²Brigham and Women's Hospital, Harvard Medical School, Boston, ³Brigham and Women’s Hospital and Harvard Medical School, Boston, ⁴Brigham and Women's Hospital, Boston, MA
Background/Purpose: The prevalence of interstitial lung disease (ILD) among rheumatoid arthritis (RA) patient ranges between 5-10%. ILD leads to high morbidity and mortality in patients…
Abstract Number: 280 • 2019 ACR/ARP Annual Meeting
Ultrasound versus Conventional Treat-To-Target Strategies in Early Rheumatoid Arthritis: Magnetic Resonance Imaging Outcome Data from a 2-year Randomized Controlled Strategy Trial
Ulf Sundin¹, Anna-Birgitte Aga ², Øivind Skare ³, Lena Nordberg ³, Till Uhlig ⁴, Hilde Hammer ³, Désirée van der Heijde ⁵, Tore Kvien ⁴, Siri Lillegraven ⁶ and Espen Haavardsholm ⁴, ¹Diakonhjemmet Hospital, Department of Rheumatology, Oslo, Norway. University of Oslo, Oslo, Norway, Oslo, Oslo, Norway, ²Diakonhjemmet Hospital, Department of Rheumatology, Oslo, Oslo, Norway, ³Diakonhjemmet Hospital, Department of Rheumatology, Oslo, Norway, ⁴Diakonhjemmet Hospital, Dept. of Rheumatology / University of Oslo, Faculty of Medicine, Oslo, Norway, ⁵Leiden University Medical Center, Leiden, Netherlands, ⁶Diakonhjemmet Hospital, Dept. of Rheumatology, Oslo, Norway
Background/Purpose: It has been debated whether treatment outcomes in early RA would be improved by targeting imaging remission, assessed by ultrasound or MRI, in addition…
Abstract Number: 447 • 2019 ACR/ARP Annual Meeting
Nail Abnormalities in a Cohort of Rheumatoid Arthritis Patients: Repetitive Trauma-Related Findings in Toenails Are Associated with Radiographic Damage
Virginia Pascual-Ramos¹, Silvia Méndez-Flores ¹, Judith Domínguez-Cherit ¹, Ana Gabriela Sánchez-Cárdenas ¹, Ana Barrera-Vargas ², Javier Merayo-Chalico ¹ and Irazú Contreras-Yáñez ¹, ¹Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirán", Mexico City, Distrito Federal, Mexico, ²Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirán", Mexico City, Mexico
Background/Purpose: Different dermatological changes and nail abnormalities have been reported in rheumatoid arthritis (RA) patients, some of which are specifically associated with the disease, while…
Abstract Number: 473 • 2019 ACR/ARP Annual Meeting
RA Presents in Disease Patterns Impacting Treatment Response
Kathryne Marks¹, Dana Symons ², Cynthia Crowson ³, Pamela Sinicrope ⁴ and Kelly O'Neill ⁵, ¹Rosalind Franklin University of Medicine and Science, Gurnee, IL, ²Rheumatoid Patient Foundation, Inc., Rockford, MI, ³Mayo Clinic Rochester, Rochester, ⁴Mayo Clinic, Rochester, MN, ⁵Rheumatoid Patient Foundation, Inc., Winter Springs, FL
Background/Purpose: Despite significant research on rheumatoid arthritis (RA), disease courses have not been clearly described. Like systemic lupus erythematosus and multiple sclerosis, RA displays a…
Abstract Number: 523 • 2019 ACR/ARP Annual Meeting
The Impact of Upadacitinib versus Methotrexate or Adalimumab on Individual and Composite Disease Measures in Patients with Rheumatoid Arthritis
Ronald van Vollenhoven¹, Andrew Östör ², Eduardo Mysler ³, Nemanja Damjanov ⁴, In-Ho Song ⁵, Yanna Song ⁶, Jessica Suboticki ⁵ and Vibeke Strand ⁷, ¹Amsterdam Rheumatology and Immunology Center ARC, Amsterdam, the Netherlands, Amsterdam, Netherlands, ²Cabrini Medical Centre, Monash University, Malvern, Australia, Malvern, Australia, ³Organización Medica de Investigación, Buenos Aires, Argentina, Buenos Aires, Argentina, ⁴Institute of Rheumatology, Belgrade University School of Medicine, Belgrade, Serbia, Belgrade, Serbia, ⁵AbbVie Inc., North Chicago, IL, USA, North Chicago, IL, ⁶AbbVie Inc., North Chicago, IL, USA, North Chicago, ⁷Division of Immunology/Rheumatology, Stanford University, Stanford, CA
Background/Purpose: In Phase 3 trials, upadacitinib (UPA), an oral JAK1-selective inhibitor, has been assessed as monotherapy vs MTX (SELECT-EARLY1) and in combination with MTX vs…
Abstract Number: 819 • 2019 ACR/ARP Annual Meeting
The Long Noncoding RNA HOTTIP Regulates Cell Cycle and Inflammatory Response in Hand Synovial Fibroblasts
Mojca Frank-Bertoncelj ¹, Tadeja Kuret², Ana Županič ³, Snezna Sodin-Semrl ⁴, Oliver Distler ⁵ and Caroline Ospelt ¹, ¹University Hospital Zürich, Zürich, Switzerland, ²University Hospital Zürich, Zurich, Tajikistan, ³University Hospital Zürich, Zurich, Switzerland, ⁴University Medical Center Ljubljana, Ljubljana, Slovenia, ⁵Dept. of Rheumatology, University Hospital Zürich, Zürich, Switzerland, Zürich, Switzerland
Background/Purpose: Previously we showed that the long noncoding RNA (lncRNA) HOTTIP is exclusively expressed in synovial fibroblasts (SF) from distal joints, such as small joints…
Abstract Number: 926 • 2019 ACR/ARP Annual Meeting
Methotrexate Is Associated with Reduced Cardiovascular Risk in Rheumatoid Arthritis Independent of Disease Activity Modification
Tate Johnson¹, Joshua Baker ², Punyasha Roul ¹, Harlan Sayles ¹, Grant Cannon ³, Brian Sauer ³, Ted Mikuls ⁴ and Bryant England ⁵, ¹University of Nebraska Medical Center, Omaha, NE, ²University of Pennsylvania, Philadelphia, PA, ³Salt Lake City VA Medical Center and Univeristy of Utah, Salt Lake City, UT, ⁴VA Nebraska-Western IA Health Care System & University of Nebraska Medical Center, Omaha, NE, ⁵VA Nebraska-Western IA Health Care System & University of Nebraska Medical Center, Omaha
Background/Purpose: Rheumatoid arthritis (RA) patients are at increased risk of cardiovascular disease (CVD). Methotrexate (MTX), a mainstay in the treatment of RA, appears to mitigate…
Abstract Number: 1133 • 2019 ACR/ARP Annual Meeting
Medicare Spending (2012-2017) on Disease Modifying Agents Commonly Used in Rheumatoid Arthritis
Deepan Dalal¹, Tingting Zhang ² and Theresa Shireman ², ¹Brown University, Riverside, RI, ²Brown University, Providence, RI
Background/Purpose: Biologic disease modifying agents (DMARDs) have become an integral part of rheumatoid arthritis (RA) treatment guidelines, but they are associated with a substantial increase…
Abstract Number: 1335 • 2019 ACR/ARP Annual Meeting
Tumor Necrosis Factor Alpha Inhibitor (TNF-α Inhibitor) Exposure and Risk of Hip Fracture in Veterans with Rheumatoid Arthritis: A Nested Case Control Study
Sarah Homann¹, Carlos Grijalva ¹, S. Bobo Tanner ¹ and James Morrow ¹, ¹Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Patients with rheumatoid arthritis (RA) have a much greater risk of sustaining a hip fracture than those without RA. Hip fractures cause significant morbidity…
Abstract Number: 1362 • 2019 ACR/ARP Annual Meeting
Relationship Between Waking Functions and Disease Activity in Rheumatoid Arthritis Patients Analyzed by Wearable Device
Masahiro Tada¹, Yutaro Yamada ², Koji Mandai ² and Noriaki Hidaka ¹, ¹Osaka City General Hospital, Osaka, Japan, ²Osaka City University Graduate School of Medicine, Osaka, Japan
Background/Purpose: We reported that the prevalence of sarcopenia was 28% and locomotive syndrome was 52% in patients with rheumatoid arthritis (RA)1. It is unknown that…

« Previous Page
1
…
7
8
9
10
11
…
56
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].